PFE Stock Price Today (September 2026) — Pfizer Inc. Analysis & Key Metrics 2026-09-04
Pfizer Inc. (PFE) is trading at $28.45, down 1.25% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $28.61 (0.5% upside).
- Volatility remains elevated (20.33% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.60% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $211.44B
P/E Ratio
Forward P/E: 9.83
Revenue Growth
Year over Year
Analyst Target
+0.5% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 62.32)
- Fundamentals say: Caution warranted (high leverage concerns)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $63.48B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $23.58 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.33% annualized volatility and β=0.46, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
This Is What I'd Do With Pfizer Stock Right Now
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs.
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Explore More Analysis for PFE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $28.45. The RSI (14-day) is at 62.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.61 implies 0.5% upside from current levels. Volatility is moderate at 20.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 36.95, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 9.83, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.71, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.90. Price-to-Sales is 2.55. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering PFE, the consensus price target is $28.61. This represents a 0.5% upside from the current price of $28.45. The range spans from a low target of $25.00 to a high target of $35.75, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.05%. The annualized dividend rate is $1.72 per share. The payout ratio is 226.3%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-24T00:00:00.000Z.
Key risks for Pfizer Inc. (PFE) investors include: 1. Unsustainable dividend payout ratio (226%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $63.48B. The debt-to-equity ratio is 74.25, which is moderate and generally manageable for most companies. The current ratio is 1.27, indicating adequate short-term liquidity. The quick ratio is 0.85. The company holds $11.70B in cash and equivalents. Free cash flow is positive at $12.49B, providing a cushion for debt servicing and shareholder returns.